Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-01 17:45 |
Number of voting rights as of November 30, 2023
|
English | 78.4 KB | ||
| 2023-12-01 17:45 |
Nombre de droits de vote au 30 novembre 2023
|
French | 78.6 KB | ||
| 2023-11-02 17:45 |
Nombre de droits de vote au 31 octobre 2023
|
French | 78.6 KB | ||
| 2023-11-02 17:45 |
Number of voting rights as of October 31, 2023
|
English | 78.3 KB | ||
| 2023-10-20 07:30 |
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Upd…
|
English | 127.5 KB | ||
| 2023-10-20 07:30 |
Nicox : Résultats financiers du premier semestre 2023 et du troisième trimestre…
|
French | 151.3 KB | ||
| 2023-10-20 07:00 |
Nicox : Rapport semestriel financier et d’activité 2023
|
French | 66.2 KB | ||
| 2023-10-02 17:30 |
PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOT…
|
French | 119.1 KB | ||
| 2023-10-02 17:30 |
MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF …
|
English | 78.3 KB | ||
| 2023-10-02 07:30 |
Nicox confirme son éligibilité au PEA-PME
|
French | 159.1 KB | ||
| 2023-09-01 17:45 |
Monthly Publication of the Number of Shares Composing the Share Capital and of …
|
English | 78.3 KB | ||
| 2023-09-01 17:45 |
PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOT…
|
French | 78.5 KB | ||
| 2023-08-01 17:45 |
PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOT…
|
French | 78.5 KB | ||
| 2023-08-01 17:45 |
Monthly Publication of the Number of Shares Composing the Share Capital and of …
|
English | 78.2 KB | ||
| 2023-07-19 07:30 |
Nicox : Résumé financier et point d’activité du deuxième trimestre 2023
|
French | 102.9 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
